Пиромелатин

Piromelatine is a novel investigational agent that has agonist activity at MT1 and MT2 along with agonism at 5-HT1A/1D receptors. A phase II randomized clinical trial (N 1/4 120) in primary insomnia resulted in significant improvement in insomnia symptoms.

Piromelatine known as Neu-P11 is a newer melatonin receptor agonist underdevelopmental stage. It acts on MT1, MT2, and also 5-HT1A/5- HT1D receptors. It has demonstrated improvement in the sleep cycle of primary insomnia patients and reducing sleep disturbances in Phase II clinical trial. It was found to have efficacy in maintaining deeper sleep, less arousal, and also preserving REM sleep pattern. In the clinical trial, piromelatine was well tolerated with no adverse effects on psychomotor performance the following day (She et al., 2014).